Name: PMSF
Brand: Selleck Chemicals
SKU: S3025
Availability: InStock
Rating: 5 (25 reviews)

Jump to

Quality Control

Batch: Purity: 99.91%

99.91

Related Targets	HDAC Caspase Proteasome Secretase MMP HCV Protease Cysteine Protease DPP Tyrosinase HIV Protease
Other Serine Protease Inhibitors	Leupeptin Hemisulfate Nafamostat mesilate (FUT-175) Sivelestat AEBSF HCl Gabexate Mesylate Alvelestat (AZD9668) Sivelestat sodium tetrahydrate UK-371804 HCl Ulinastatin Fulacimstat

Solubility

In vitro
Batch:

DMSO : 35 mg/mL (200.93 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 35 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	1.750mg/ml (10.05mM)	Taking the 1 mL working solution as an example, add 50 μL of 35 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	1.750mg/ml (10.05mM)	Taking the 1 mL working solution as an example, add 50 μL of 35 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

%

% Tween 80

% ddH₂O

% DMSO

+

%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	174.19	Formula	C₇H₇FO₂S	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	329-98-6	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	Phenylmethylsulfonyl Fluoride, Benzylsulfonyl fluoride			Smiles	C1=CC=C(C=C1)CS(=O)(=O)F

Mechanism of Action

Targets/IC₅₀/Ki	cysteine protease chymotrypsin
In vitro	Although human trypsin is less susceptible to inhibition by PMSF, this compound rapidly inactivates purified chymotrypsin from human pancreas. It also rapidly inhibits acetylcholinesterase from human red cells. As an inhibitor of phosphatidylinositol-specific phospholipase C, treatment with this chemical at 2 mM almost completely inhibits carbachol-stimulated inositol incorporation into phosphatidylinositol (PI) of longitudinal smooth muscle of guinea pig ileum, while it has no effect on potassium-stimulated inositol incorporation. In contrast to its specific inhibition of carbachol-stimulated phosphoinositide turnover, this agent produces a transient inhibition of contraction by both carbachol and potassium. It has been shown to inhibit the addition of ethanolamine phosphate to glycosylphosphatidylinositol (GPI) intermediates in Trypanosoma brucei. This inhibitor also inhibits the acylation of the inositol residue of GPI intermediates in bloodstream form T. brucei. It inhibits ethanolamine phosphate addition and inositol acylation for procyclic forms of T. brucei but not for mammalian HeLa cells. This compound is the more reactive inactivator of mouse acetylcholinesterase (AChE), as the 8-fold higher BSF concentration is necessary to achieve even a 6-fold slower inactivation than that using PMSF.
In vivo	Intraperitoneal injection of PMSF produces dose-dependent analgesia in Sprague-Dawley rats. This compound significantly enhances the analgesic effect of beta-endorphin (END) in rats. Mice receiving i.p. injections of this chemical exhibit cannabinoid effects that include antinociception, hypothermia and immobility with ED50 of 86 mg/kg, 224 mg/kg and 206 mg/kg, respectively. Pretreatment with an inactive dose of this compound (30 mg/kg) enhances the effects of anandamide on tail-flick response (antinociception), spontaneous activity and mobility by 5-, 10- and 8-fold, respectively. Administration of this chemical 12 hours prior to PSP causes complete protection in organophosphorus ester-induced delayed neuropathy (OPIDN) in hens, but it administered 4 hours after PSP potentiates its neurotoxic effects. Pretreatment with this compound (30 mg/kg, i.p.) prior to an injection of 1 or 10 mg/kg 3H-anandamide results 5 minutes later in enhanced brain levels of anandamide compared to those obtained with 3H-anandamide plus vehicle injection. Pretreatment with it inhibits tri-ortho-cresyl phosphate (TOCP)-induced neurofilament (NF) degradation, and protects hens against the development of organophosphate-induced delayed neuropathy (OPIDN). Administration of this chemical enhances the characteristic cannabimimetic effects of Δ(9)-tetrahydrocannabinol (THC) or anandamide (AEA) in ICR mice, by inhibiting the enzyme fatty acid amide hydrolase.
References	[1] https://pubmed.ncbi.nlm.nih.gov/4306345/ [2] https://pubmed.ncbi.nlm.nih.gov/6292607/ [3] https://pubmed.ncbi.nlm.nih.gov/6090026/ [4] https://pubmed.ncbi.nlm.nih.gov/7518442/ [5] https://pubmed.ncbi.nlm.nih.gov/9399986/ [6] https://pubmed.ncbi.nlm.nih.gov/10591511/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04062786	Unknown status	Scheduled Heart Surgery\|Valve Replacement\|Coronary Artery Bypass	University Hospital Strasbourg France	February 21 2019	--
NCT03300323	Unknown status	Peri-operative Fluid Management	St George''s Healthcare NHS Trust	October 2017	Not Applicable
NCT02569008	Completed	Post Cardiac Surgery	St George''s University of London	January 2014	Not Applicable

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

PMSF Serine Protease inhibitor

Chemical Structure

Molecular Weight: 174.19